ARTELO BIOSCIENCES, INC. 8-K

What Happened

• Artelo Biosciences, Inc. (ARTL) adjourned its 2025 annual meeting on December 31, 2025 due to lack of a quorum and scheduled reconvening for 8:00 a.m. PT on January 30, 2026 to allow additional shareholder votes (including a ratification of Malone Bailey LLP as auditor). The company notified Nasdaq on January 12, 2026 of the adjournment. On January 14, 2026 Nasdaq staff sent a notice saying Artelo is not in compliance with Nasdaq Listing Rule 5620(a) (the annual‑meeting rule), and that this deficiency could be a basis for delisting. The Nasdaq notice does not have immediate effect on the listing; the company addressed this issue in its hearing presentation before a Nasdaq Hearing Panel, which also considered the company’s earlier disclosed $2.5 million minimum stockholders’ equity deficiency under Listing Rule 5550(b)(1).

Key Details

• Annual meeting adjourned: December 31, 2025; reconvened: January 30, 2026 at 8:00 a.m. PT.
• Nasdaq notified the company of annual‑meeting rule non‑compliance on January 14, 2026.
• The company previously disclosed a $2.5 million stockholders’ equity deficiency under Listing Rule 5550(b)(1) and is in hearings with Nasdaq.
• The Nasdaq notice “could” be a basis for delisting; however, Artelo’s common stock remains listed and traded pending the hearing outcome or any extension.

Why It Matters

• For investors, the filing signals potential listing risk: non‑compliance with Nasdaq rules (annual meeting and an outstanding equity deficiency) can lead to delisting if not cured or if the Hearing Panel does not grant relief. Delisting would likely reduce liquidity and could negatively affect share value. The company says it intends to take all reasonable measures to regain compliance, but explicitly notes there is no assurance of success. Currently, trading continues while the hearings process plays out.